# Development and characterization of the genotype F attenuated mumps candidate strains

## TL;DR

Researchers developed two safe and effective mumps vaccine candidates based on the prevalent genotype F virus in China.

## Contribution

Development of two genotype F attenuated mumps virus strains with strong immunogenicity and low neurotoxicity.

## Key findings

- QBB-2BS-3.2 and QBB-2BS-9.3 induced strong neutralizing antibodies in mice.
- Both strains showed minimal neurotoxicity in neonatal rats.
- The strains offer a foundation for genotype F mumps vaccine development.

## Abstract

Mumps is an acute infectious disease caused by the mumps virus (MuV), primarily affecting the parotid glands, though it can also lead to systemic infections, including the nervous system. In China, the predominant circulating MuV genotype is F, while the vaccine strain (S79 or WM84) belongs to genotype A, raising concerns about immunization effectiveness.

A genotype F MuV strain was isolated from throat swabs of six suspected mumps patients. Through cell adaptation passage and plaque purification, two candidate vaccine strains QBB-2BS-3.2 and QBB-2BS-9.3 were prepared. Their immunogenicity was assessed by neutralizing antibody and cell-mediated immune responses in immunized mice. Additionally, neurotoxicity was evaluated in neonatal Lewis rats.

Both QBB-2BS-3.2 and QBB-2BS-9.3 elicited strong neutralizing antibody responses and robust cell-mediated immune responses in mice. Notably, neurotoxicity testing revealed minimal neurotoxicity in QBB-2BS-3.2 and QBB-2BS-9.3 strains, comparable to the S79 vaccine strain.

This study successfully developed two attenuated genotype F MuV candidate strains with favorable immunogenicity and safety profiles, laying a critical foundation for the development of genotype F mumps live attenuated vaccines.